NCT04701385 (PEPSii) is a clinical trial of Optical Coherence Tomography (OCT) in Atheroma; Myocardial, sponsored by Norfolk and Norwich University Hospitals NHS Foundation Trust.

Who is sponsoring NCT04701385?

NCT04701385 is sponsored by Norfolk and Norwich University Hospitals NHS Foundation Trust.

What drugs are being tested in NCT04701385?

Interventions in NCT04701385: Optical Coherence Tomography (OCT).

What condition does NCT04701385 study?

NCT04701385 studies Atheroma; Myocardial.

Is NCT04701385 still recruiting?

NCT04701385 is currently completed. Last updated 18 December 2023.

Last reviewed 2023-12-18 · How we verify

NCT04701385: PEPSii

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plaque Erosion Prospective Study ii

Completed Last updated 18 December 2023

What this trial tests

trial testing Optical Coherence Tomography (OCT) in Atheroma; Myocardial in 33 participants. Completed in 31 January 2023.

Timeline

15 October 2020

Primary endpoint
31 January 2022

31 January 2023

Quick facts

Lead sponsor	Norfolk and Norwich University Hospitals NHS Foundation Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	33
Start date	15 October 2020
Primary completion	31 January 2022
Estimated completion	31 January 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Optical Coherence Tomography (OCT)

Conditions studied

Atheroma; Myocardial — all drugs for Atheroma; Myocardial →

Sponsor

Norfolk and Norwich University Hospitals NHS Foundation Trust

Who can join

Adults 18 to 75, any sex, with Atheroma; Myocardial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Plaque erosion is associated with myocardial infarction (MI) in about 30% of cases and may require a different management approach to plaque rupture. The investigators hypothesise that plaque erosion leads to higher levels of apoptotic circulating endothelial cells (CECs) compared to plaque rupture. Aims: To compare associations between plaque erosion and plaque rupture with numbers and types of apoptotic CECs in patients with non-ST elevation MI (NSTEMI) and stable coronary artery disease controls (CAD). Additional aims are to explore signals of cellular stress (mitochondrial dsDNA), sub-populations of activated neutrophils, circulating endothelial progenitor cells and erosion-specific plasma biomarkers. Methods: Prospective observational study of 80 patients with NSTEMI and 40 patients with stable CAD. Plaque erosion or rupture will be identified by intracoronary Optical Coherence Tomography (OCT). CECs and neutrophils will be quantified and characterised using flow cytometry looking at markers of cell death and neutrophil activation. Plasma will be analysed by proteomic methods (Olink) and for mitochondrial dsDNA. Potential importance of findings: This study will provide evidence for the hypothesised mechanism of plaque erosion and clarify if biomarker analysis in NSTEMI patients provides a basis for non-invasive diagnosis of plaque erosion versus rupture.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Precision Medicine in Acute Coronary Syndromes.
Caffè A, Animati FM, Iannaccone G, Rinaldi R, et al · · 2024 · cited 3× · PMID 39124834 · DOI 10.3390/jcm13154569

Verify or expand the search:

Other trials of Optical Coherence Tomography (OCT)

Trials testing the same drug.

NCT07434362 — Serum Endocan, Alarin, and Galanin-Like Peptide Levels in Diabetic Retinopathy · NA · completed
NCT06976034 — oCular Examination at Cell RESolution With Optical TransmissionTomography · NA · recruiting
NCT04510727 — Optical Coherence Tomography Guided C&D · NA · withdrawn
NCT05161546 — Study of Bipolar Disorders and Retinal Electrophysiological Markers · NA · terminated
NCT04774822 — Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device · completed

Other Norfolk and Norwich University Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07027098 — Influence of Perfluorocarbon Liquid (LIQUID) During Pars Plana Vitrectomy on Retinal Vessel Displacement in Primary Macu · NA · recruiting
NCT07163962 — THE B-BABIES STUDY: An Observational Study of Group B Vitamins in Preterm Infants · not yet recruiting
NCT06856122 — Pharmacogenomics to Improve Supportive Care Symptoms. · enrolling by invitation
NCT06186505 — Heat Therapy for Peripheral Arterial Disease (HEATPAD) · NA · not yet recruiting
NCT06910800 — Indwelling Pleural Catheters: a Self-management Intervention · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04701385 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Norfolk and Norwich University Hospitals NHS Foundation Trust
Last refreshed: 18 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04701385.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing